A transplantation study reported successful conversion of donor blood group antigens using an enzymatic process that produced O-type kidneys eligible for broader use. The enzyme-conversion approach allows ABO-incompatible grafts to be reclassified, potentially expanding the donor pool and shortening wait times for patients. The report detailed perioperative outcomes and immunologic monitoring showing acceptable safety signals in early recipients. Investigators emphasized the clinical potential to reduce reliance on desensitization protocols that primarily target recipients. If validated in larger cohorts, enzymatic antigen conversion could reshape organ allocation, reduce discard rates and alter center-level transplant logistics and economics.